Holen Sie sich die Stockscreener-App
48.19
1.69%
0.80
Handel nachbörslich:
48.19
Schlusskurs vom Vortag:
$47.39
Offen:
$46.95
24-Stunden-Volumen:
1.05M
Relative Volume:
1.22
Marktkapitalisierung:
$3.56B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.1128
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+6.90%
1M Leistung:
-15.66%
6M Leistung:
+25.36%
1J Leistung:
+90.32%
1-Tages-Spanne:
$46.71
$49.41
1-Wochen-Bereich:
$44.42
$49.41
52-Wochen-Spanne:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.19 | 3.56B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Alpha DNA Investment Management LLC Buys Shares of 10,258 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
XTX Topco Ltd Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Earnings on Tuesday - MarketBeat
Jump Financial LLC Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Trading Up 6.8%What's Next? - MarketBeat
Lobbying Update: $20,000 of PTC THERAPEUTICS lobbying was just disclosed - Nasdaq
Walleye Capital LLC Invests $4.97 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Federated Hermes Inc. Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million - Quantisnow
Russell Investments Group Ltd. Sells 61,542 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Renaissance Technologies LLC Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results - Quantisnow
MELAS Syndrome Therapeutics Market Size in 7MM is expected - openPR.com
PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results | PTCT Stock News - GuruFocus
PTC Therapeutics Reveals Q1 2025 Earnings Date: Key Financial Updates Coming May 6 - Stock Titan
Cautious Hold Rating for PTC Therapeutics Amidst FDA Reviews and Revenue Uncertainties - TipRanks
Alliancebernstein L.P. Buys 139,596 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
ADAR1 Capital Management LLC Purchases 28,023 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
American Century Companies Inc. Has $2.72 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results - marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Headlands Technologies LLC - MarketBeat
Lee Scott Golden Sells 897 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Leigh Syndrome Treatment Market Set to Witness Significant - openPR.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Vanguard Group Inc. - MarketBeat
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Business And Shares Still Trailing The Industry - simplywall.st
Wellington Management Group LLP Decreases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Trexquant Investment LP Has $14.15 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
14,300 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by KLP Kapitalforvaltning AS - MarketBeat
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 By Investing.com - Investing.com Australia
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 - Investing.com
PTC Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
PTC Therapeutics (NASDAQ:PTCT) Shares Down 8.8% Following Analyst Downgrade - MarketBeat
Pictet Asset Management Holding SA Buys 381,319 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given New $75.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):